Clinical Trial Search

Primary: Maximum Measured Concentration (Cmax) of the Analytes in Plasma — 697; 726; 3.62; 3.57 ng/mL

Primary: Change in Dietary Quality Scores of Members as Measured Using the 2005 Healthy Eating Index (HEI). — 5.2; 4.5 points

Primary: Demographical Characteristics of Participants — 20; 11; 39; 19 participants

Primary: Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 — -12.5; -18.6; -18.5 score on a scale — p=<0.001

Primary: Montgomery Asberg Depression Rating Scale (MADRS) — 14.9 units on a scale — p=<0.00001

Primary: Change in Percent Collagen I Deposition on Lymph Node Pathology From Baseline to Week 48 — -2.44; -6.08 percent area stain positive — p=0.97

Primary: Number of Participants Who Received At Least 1 Infusion of Sipuleucel-T in Men With Metastatic Castrate-resistant Prostate Cancer (CRPC) — 98 participants

Primary: Incidence of Post-operative Nausea and/or Vomiting — 29; 24 Participants

Primary: Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitides Serogroups A, C , W-135, Y (hSBA-MenA, hSBA-MenC , hSBA-MenW -135…

Primary: Time to Prostate-specific Antigen (PSA) Progression — 8.31; 2.86 Months — p=<0.0001

Primary: Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 6; 4; 6; 5 Participant

Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants

Primary: Mean Pain Intensity (NRS) — 5.93; 5.89 units on a scale — p=0.834

Primary: Normal Biodistribution of 68Ga-DOTA-Bombesin — 2.28; 121.55; 0.08; 0.10 SUV-mean

Primary: Number of Subjects With Symptomatic Intracerebral Hemorrhage — 1; 1 Participants